Kymab forms cancer drug alliance with US university
Cambridge-based Kymab, which specialises in human monoclonal antibody technology, is working with a leading US university on a new cancer drug discovery and development programme.
The UK business has entered an alliance with The University of Texas MD Anderson’s Oncology Research for Biologics and Immunotherapy Translation (ORBIT) unit.
The collaboration will focus on developing novel monoclonal antibodies as well as on identifying biomarkers for identification of responder populations. The agreement is for an initial period of five years.
Kymouse – Kymab’s human antibody discovery platform – is regarded as having unparalleled diversity. It is said to yield antibodies with reportedly highly attractive drug-like properties and rapidly identify and enrich rare high-quality molecules that can be explored as novel therapeutics.
The agreement will utilise each partner’s complementary skills, resources and capabilities to develop innovative new drugs for cancer. The collaboration will combine Kymab’s industry-leading antibody platform, in-house discovery and development experience together with MD Anderson’s novel target biology, clinical datasets, translational and clinical infrastructure to develop products to clinical proof of concept and ultimately for submission for FDA approval.
David Chiswell, chairman and CEO of Kymab, said: “Together, Kymab and MD Anderson bring power and skills to a partnership committed to efficiency and speed in delivering novel immunotherapies through the use of world-class science. Immuno-oncology is an exceptionally promising field of research and a key focus for Kymab.”
Carlo Toniatti, executive director of ORBIT added: “These are exciting times for the development of monoclonal antibodies for cancer immunotherapy. This alliance presents a great opportunity to leverage our translational and clinical expertise and develop innovative antibody drugs vital to helping patients in their fight against cancer.”